Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed metastatic solid tumor

- Disease progressed during at least one standard therapy OR has a disease for
which there is no standard therapy

- No squamous cell carcinoma of the lung

- Asymptomatic brain metastases allowed provided both of the following criteria are
met:

- Brain metastases were treated ≥ 6 months ago

- Brain metastases are clinically stable without steroid treatment for 1 week

- No clinically relevant pleural effusions or ascites that cannot be controlled by
drainage (group 2)

PATIENT CHARACTERISTICS:

- ECOG performance status 0-1

- Hemoglobin ≥ 9.0 g/dL

- ANC ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

- ALT and AST ≤ 2.5 times ULN

- INR < 1.5 or PT/PTT normal

- Creatinine clearance ≥ 45 mL/min

- Negative serum pregnancy test

- Fertile patients must use effective contraception during and for at least 2 weeks
after completion of study treatment

- No New York Heart Association class III or IV congestive heart failure

- No unstable angina (anginal symptoms at rest) or new onset angina (within the past 3
months)

- No myocardial infarction within the past 6 months

- No cardiac ventricular arrhythmias requiring anti-arrhythmic therapy

- No uncontrolled hypertension, defined as systolic blood pressure > 150 mm Hg or
diastolic blood pressure > 90 mm Hg, despite optimal medical management

- No known severe hypersensitivity to sorafenib tosylate or any its excipients,
etoposide, pemetrexed disodium, cisplatin, or carboplatin

- No known HIV infection

- No chronic hepatitis B or C

- No active clinically serious infection > CTCAE grade 2

- No thrombotic or embolic events, such as cerebrovascular accident or transient
ischemic attacks, within the past 6 months

- No pulmonary hemorrhage or bleeding event ≥ CTCAE grade 2 within the past 4 weeks

- No other hemorrhage or bleeding event ≥ CTCAE grade 3 within the past 4 weeks

- No serious non-healing wound, ulcer, or bone fracture

- No evidence or history of bleeding diathesis or coagulopathy

- No condition that impairs the patient's ability to swallow whole pills

- No malabsorption problem, uncontrolled inflammatory bowel disease, or
gastrointestinal disorder causing ≥ 5 bowel movements in a 24-hour period

- No significant traumatic injury within the past 4 weeks

- Able to take vitamin B12 supplementation and folic acid (group 2)

PRIOR CONCURRENT THERAPY:

- More than 4 weeks since prior major surgery or open biopsy

- No more than 3 prior cytotoxic therapies for metastatic disease

- No concurrent St. John's wort or rifampin

- No non-steroidal anti-inflammatory drugs (NSAIDs) for 2 days before (5 days for
long-acting NSAIDs), during, and for 2 days after pemetrexed disodium administration
(group 2)

- Concurrent anticoagulation treatment with warfarin or heparin allowed